Device Trial Radar · NCT01307501
Safety and Efficacy of Cryoablation for Metastatic Lung Tumors
Last checked: Nov 19, 2026Latest source record: Jul 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jan 4, 2012
Primary completion
Aug 30, 2018
Study completion Aug 30, 2018
Sponsor
- Lead sponsor
- Boston Scientific CorporationPublic (BSX)
- Sponsor type
- Industry
- First posted
- Mar 3, 2011
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ECLIPSE will evaluate the safety and efficacy of cryoablation therapy used to treat tumors less than or equal to 3.5 centimeters (cm) in participants with pulmonary metastatic disease.
Conditions
- Metastatic Lung Cancer
Interventions
CryoablationDevice
Application of extremely cold temperatures to the identified tumor(s).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Local Tumor Control for Each Index Tumor as Measured by Imaging at Month 60Time frame: Baseline and Month 60
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Ronald Regan UCLA Medical Center
Los Angeles, California
Karmanos Cancer Institute
Detroit, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.